Charles Schwab
IBIO icon

Charles Schwab’s iBio IBIO Stock Holding History

Charles Schwab’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-362
Closed -$31K – 3555
2022
Q3 		$31K Buy
+362
New +$49.8K ﹤0.01% 3424
2022
Q2 		– Sell
-1,172
Closed -$252K – 3589
2022
Q1 		$252K Buy
1,172
+108
+10% +$22.6K ﹤0.01% 3269
2021
Q4 		$293K Hold
1,064
– – ﹤0.01% 3291
2021
Q3 		$565K Hold
1,064
– – ﹤0.01% 3106
2021
Q2 		$804K Buy
1,064
+4
+0.4% +$2.92K ﹤0.01% 3003
2021
Q1 		$817K Buy
1,060
+161
+18% +$140K ﹤0.01% 2918
2020
Q4 		$473K Buy
899
+511
+132% +$416K ﹤0.01% 3009
2020
Q3 		$394K Buy
388
+104
+37% +$151K ﹤0.01% 2952
2020
Q2 		$316K Buy
+284
New +$186K ﹤0.01% 3018

Other funds holding IBIO

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Charles Schwab's IBIO Position: Q4 2022 in Review

Charles Schwab sold out of iBio (IBIO) in Q4 2022, closing a stake of 362 shares — an estimated $31K sold.

Charles Schwab first reported a position in IBIO in Q2 2020 and held it in 9 quarters. The position peaked at $817K in Q1 2021. 36 funds tracked by Wall St. Rank hold IBIO as of Q4 2022.

  • Charles Schwab reported no remaining iBio position as of Q4 2022 after selling out during the quarter.
  • Charles Schwab sold 362 iBio shares in Q4 2022, an estimated $31K.
  • Charles Schwab first reported a position in iBio in Q2 2020 and held it in 9 quarters.
  • Charles Schwab's iBio position peaked at $817K in Q1 2021.
  • 36 funds tracked by Wall St. Rank held iBio as of Q4 2022.

Based on Charles Schwab's 13F filing for Q4 2022, filed 13 Feb 2023.